^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:HER2 Positive Breast Cancer
    Drug:MK-2206 (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

    Excerpt:
    ...- Patients must be women with histologically or cytologically confirmed Her2 positive (3+ by immunohistochemistry [IHC] or fluorescence in situ hybridization [FISH] ratio >= 2.0) advanced breast cancer that is metastatic or unresectable and for which standard curative or palliative measures do...
    Trial ID:
    NCT01281163
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.

    Published date:
    05/26/2022
    Excerpt:
    HER2+/Luminal appeared to be more sensitive to the AKT inhibitor MK2206 than to targeted HER2 agents, though numbers are small.
    DOI:
    10.1200/JCO.2022.40.16_suppl.510
    Trial ID:
    I-SPY 2